Mark Knight


Authored Items

New Androgen Receptor–Signaling Inhibitor Extends Survival, Improves QOL in Advanced Prostate Cancer

July 2012, Vol 3, No 5 - ASCO Annual Meeting

Chicago, IL—The novel androgen receptor–signaling inhibitor enzalutamide, also known as MDV3100, significantly prolonged overall survival (OS), slowed disease progression, and improved quality-of-life (QOL) measures in men with castration-resistant prostate cancer after docetaxel failure, according to results from a large phase 3 clinical trial.

[ Read More ]

High OOP Costs for Medicare Patients with Cancer

July 2012, Vol 3, No 5 - ASCO Annual Meeting

Chicago, IL—Older patients with cancer and Medicare coverage often incur greater out-of-pocket (OOP) expenses compared with their counterparts without cancer. Factors contributing to the greater expenses for those patients include comorbidities and lack of supplemental insurance. As a result, older patients often hesitate to seek treatment for cancer because of financial concerns, according to a study presented by Amy J. [ Read More ]

Regenerative Medicine the Focus of Presidential Symposium

January 2013, Vol 4, No 1 - ASH Annual Meeting

Atlanta, GA—The promise of regenerative medicine is exemplified by the regeneration of corneal epithelium from human limbal stem-cell culture.

The fields of regenerative medicine and hematology are relevant to one another, said Armand Keating, MD, Chair in Cell Therapy and Transplantation Director, Division of Hematology, University of Toronto, Canada and President of the American Society of Hematology (ASH) during the ASH 2012 Presidential Symposium, which focused on advances in regenerative medicine.

[ Read More ]

Nab-Paclitaxel Added to Gemcitabine Extends Survival in Patients with Metastatic Pancreatic Cancer

February 2013, Vol 4, No 2 - GI Cancers Symposium

San Francisco, CA—A new “backbone” of therapy for metastatic pancreatic cancer could be the combination of nab-paclitaxel (Abraxane) and gemcitabine (Gemzar). When added to gemcitabine, weekly nab-paclitaxel improved survival in patients with advanced pancreatic cancer by nearly 2 months compared with gemcita­bine alone, said Daniel D. Von Hoff, MD, FACP, Physician in Chief and Director of Translational Research, Translational Genomics Research Institute, Phoenix, regarding the results of a large international phase 3 clinical trial.

[ Read More ]

New Antibody Targeting VEGF Receptor-2 Extends Survival in Advanced Gastric Cancer

February 2013, Vol 4, No 2 - GI Cancers Symposium

San Francisco, CA—Ramucirumab as a second-line therapy extended overall and progression-free survival in a phase 3 clinical trial of patients with metastatic gastric cancer, said Charles S. Fuchs, MD, MPH, Director of the Center for Gastrointestinal Cancer at Dana-Farber Cancer Institute, Boston, and Professor of Medicine at Harvard Medical School, at the 2013 Gastrointestinal Cancers Symposium.

[ Read More ]